Orexo settles DOJ investigation
Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Sep 01, 2026
The announcement removes a long-standing overhang from the DOJ investigation, likely reducing legal uncertainty for Orexo. The stock rose 8.63% following the news, reflecting positive market sentiment, though the settlement amount is modest relative to the company's market cap.
Orexo, a Swedish pharmaceutical company, announced on August 31, 2026, that it has reached a non-binding agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation that has been ongoing since 2020. The proposed settlement includes a Non-Prosecution Agreement (NPA) and a separate civil settlement, with no admission of wrongdoing by Orexo or its employees. Under the terms, Orexo would pay United States — United States dollar 4 million in installments over several years and commit to a capped contingent payment equal to five percent of net sales, conditional on certain sales thresholds being met in 2030-2031. Two former Orexo US employees have also reached agreements in principle to resolve civil claims, and Orexo intends to seek insurance coverage for their settlement amounts. CEO Nikolaj Sørensen emphasized that the decision to settle is pragmatic, allowing the company to avoid significant costs and focus on development. Orexo expects to recognize a provision of United States — United States dollar 4 million for the expected liability. The final settlement agreement is not yet concluded, and there is no assurance it will be entered into on these terms.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard